Skip to main content

Table 2 VTEs according to treatment arm, histologic subtype and treatment phase

From: High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08

 

Overall

N = 300

Investigational Arm

N = 149

Control Arm

N = 151

Adeno-carcinoma

N = 189

Squamous Cell Carcinoma

N = 111

Overall (N)

8.7% (26b)

9.4% (14a)

7.9% (12)

11.1% (21a)

4.5% (5)

Preoperative (N = 300)

6.7% (20b)

8.0% (12a)

5.3% (8)

9% (17a)

2.7% (3)

Ind-CT

1.3% (4)

1.3% (2)

1.3% (2)

1.6% (3)

0.9% (1)

RCT

5.6% (16b)

7.1% (10a)

4.1% (6)

7.7% (14a)

1.9% (2)

Postoperative (N = 259)

3.1% (8)

3.1% (4)

3.1% (4)

3.5% (6)

2.3% (2)

  1. aOne of these patients had two simultaneous grade 3 VTEs in the RCT phase
  2. bTwo of these patients had two separate grade 3 VTEs at different time points